Permission to Live: How Insurance Pre-Authorization Became the Administrative Sentence That Kills Americans Before Their Care Is Approved

The Form Before the Treatment

In the spring of 2023, a 17-year-old in Georgia named Alexus Ochoa died after her insurer, United Healthcare, denied coverage for a residential mental health treatment program that her psychiatrist had recommended following a suicide attempt. Her family spent weeks navigating the appeals process. The denial was eventually overturned — after her death. Her case drew national attention, became the subject of congressional testimony, and then, like most such cases, faded from the news cycle without producing a single binding policy change.

Alexus Ochoa's story is not an anomaly. It is, according to a growing body of data from physicians, patient advocates, and state insurance regulators, a predictable outcome of a system designed to interpose bureaucratic friction between patients and care. That system is called prior authorization — or pre-authorization — and it is one of the most consequential and least publicly understood features of American health insurance.

The American Medical Association's 2023 Prior Authorization Physician Survey found that 94 percent of physicians reported that prior authorization delays care, and 33 percent reported that the process had led to a serious adverse event for a patient in their care — including hospitalization, permanent disability, or death. These are not fringe findings from an advocacy organization. They are responses from practicing physicians across specialties, describing their daily experience of a system that requires them to justify clinical decisions to insurance company reviewers who are frequently not licensed in the relevant specialty and are operating under productivity targets that incentivize denial.

What Pre-Authorization Actually Is — and What It Claims to Be

Insurers frame prior authorization as a utilization management tool: a clinical safeguard that ensures treatments are medically necessary, evidence-based, and appropriate before the company commits to paying for them. In its most honest version, this argument acknowledges that American healthcare does include genuine overutilization — unnecessary procedures, redundant imaging, and low-value interventions that drive up costs without improving outcomes.

This is a real problem. It is not, however, what prior authorization primarily addresses in practice.

A 2022 report from the House Energy and Commerce Committee, based on data obtained from major insurers, found that prior authorization denial rates varied dramatically across insurers and bore little consistent relationship to clinical evidence or utilization guidelines. UnitedHealth Group, the nation's largest insurer, denied prior authorization requests at a rate that was significantly higher than the industry average in several categories of care. Cigna, in reporting by ProPublica, was found to have had reviewers deny claims in batches of tens of thousands without meaningful individual review — a process the company's own former medical director described as assembly-line denial.

The financial logic is not subtle. Prior authorization creates delay. Delay produces abandonment — patients who cannot navigate the appeals process, who cannot afford to wait, or who are simply too sick to fight. Abandoned claims are claims the insurer never pays. In a business model defined by the spread between premiums collected and claims paid — the medical loss ratio — every abandoned authorization is a contribution to the bottom line.

UnitedHealth Group reported net earnings of $22.4 billion in 2023. Cigna reported $5.2 billion. Elevance Health (formerly Anthem) reported $6 billion. These are not the margins of companies rationing resources out of fiscal necessity. They are the margins of companies that have optimized their administrative systems for claim suppression.

The Burden Falls Hardest on Those Who Can Least Carry It

The pre-authorization burden is not distributed equally. It falls most heavily on the patients least equipped to carry it.

Navigating a prior authorization denial requires time — to call the insurer, to gather documentation, to file an appeal, to follow up, to potentially engage an attorney or patient advocate. It requires literacy — in insurance policy language, clinical terminology, and bureaucratic procedure. It requires persistence — the willingness to make the same call for the fourteenth time, to escalate, to threaten a complaint to the state insurance commissioner. And it requires the physical and cognitive capacity to do all of this while managing a serious illness.

Low-income workers, people of color, patients with cognitive impairments, and individuals without access to a sophisticated primary care physician who can advocate on their behalf are systematically disadvantaged in this process. Research published in Health Affairs has documented that Black and Hispanic patients face prior authorization denials at higher rates than white patients with comparable diagnoses and insurance coverage, and are less likely to successfully appeal those denials. The administrative architecture of prior authorization does not create racial health disparities — but it amplifies and enforces them.

For workers without paid sick leave or flexible schedules, the time cost of navigating an authorization appeal can be prohibitive. A study by the advocacy group Aimed Alliance found that prior authorization processes consume an average of nearly two business days per week of physician practice staff time — a burden that is ultimately passed on to patients through reduced access and longer wait times even for approved care.

The Strongest Case for Prior Authorization

The insurance industry's defense of prior authorization deserves a fair hearing before it is rejected. Insurers point to evidence that some categories of care — particularly elective surgical procedures and high-cost specialty drugs — are genuinely overutilized in the American system, and that without utilization review, costs would rise further in a market already defined by price opacity and supplier-induced demand. Some academic research does find that well-designed utilization management can reduce low-value care without harming outcomes.

This argument has merit in a narrow sense. The problem is that the prior authorization system as it actually operates bears little resemblance to the careful, evidence-based utilization management that the industry describes. When a psychiatrist's recommendation for inpatient mental health treatment is denied by a reviewer who spent less than ten minutes on the file, that is not evidence-based utilization management. When an oncologist's chemotherapy protocol is delayed for three weeks while an insurance company processes paperwork, that is not a clinical safeguard. It is a financial delay tactic with a clinical costume.

The solution is not the elimination of all utilization oversight. It is the replacement of the current system with one that is transparent, time-limited, specialty-appropriate, and subject to meaningful regulatory accountability — which the current system emphatically is not.

Regulation Has Lagged Years Behind the Harm

Federal law does not currently impose binding time limits on prior authorization decisions for commercial insurance plans. The No Surprises Act of 2022 addressed surprise billing but left prior authorization largely untouched. A bipartisan bill — the Improving Seniors' Timely Access to Care Act — passed the House with overwhelming support in 2022 and would have imposed modest prior authorization reforms for Medicare Advantage plans. It died in the Senate.

In 2024, the Centers for Medicare and Medicaid Services finalized a rule requiring shorter decision timelines and greater transparency for prior authorization in Medicare Advantage and Medicaid managed care plans — a meaningful step, but one that covers only a portion of the insured population and does not address the commercial market where the most aggressive denial practices are concentrated.

Nearly half of U.S. states have passed some form of prior authorization reform legislation, but the scope and enforcement mechanisms vary enormously. In states without strong consumer protections, insurers operate with near-total discretion.

The Stakes Are Not Abstract

Behind every prior authorization statistic is a person who needed care and was told to wait. A child whose autism therapy was delayed by eight months while her parents appealed a denial. A man whose cardiac procedure was postponed until his condition deteriorated to the point of emergency surgery. A woman whose breast reconstruction following mastectomy was denied as "cosmetic" by a reviewer who had never read her surgical notes.

These are not rare edge cases. The AMA survey found that 24 percent of physicians reported a patient experienced a life-threatening event as a result of prior authorization delay. In a country with more than 300 million insured lives, the arithmetic of that percentage is not a policy footnote. It is a public health emergency conducted on a slow timeline, one denial at a time.

A healthcare system that requires the sick to earn their treatment through administrative endurance is not a system built around health. It is a system built around profit — and until prior authorization is treated as the patient safety crisis it demonstrably is, that system will keep collecting its dividend in human lives.